These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9832347)

  • 41. Haloperidol plasma levels and acute clinical change in schizophrenia.
    Coryell W; Kelly M; Perry PJ; Miller DD
    J Clin Psychopharmacol; 1990 Dec; 10(6):397-402. PubMed ID: 2286709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
    Kuhs H; Folkerts H
    Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
    Libiger J; Czobor P; Volavka J
    Psychiatry Res; 1994 May; 52(2):107-14. PubMed ID: 7972567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
    Skogh E; Sjödin I; Josefsson M; Dahl ML
    J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
    Ulrich S; Meyer FP; Neuhof S; Knorr W
    J Chromatogr B Biomed Appl; 1995 Jan; 663(2):289-96. PubMed ID: 7735476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radio receptor assay of serum neuroleptic levels in psychiatric patients.
    Krska J; Sampath G; Shah A; Soni SD
    Br J Psychiatry; 1986 Feb; 148():187-93. PubMed ID: 2870755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis.
    Swigar ME; Jatlow PI; Goicoechea N; Opsahl C; Bowers MB
    Am J Psychiatry; 1984 Oct; 141(10):1281-3. PubMed ID: 6486269
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
    Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
    Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
    Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations.
    Calil HM; Avery DH; Hollister LE; Creese I; Snyder SH
    Psychiatry Res; 1979 Jul; 1(1):39-44. PubMed ID: 45128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring.
    Fukuda R
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Nov; 24(8):1299-318. PubMed ID: 11125855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients.
    Tune LE; Creese I; DePaulo JR; Slavney PR; Snyder SH
    J Nerv Ment Dis; 1981 Jan; 169(1):60-3. PubMed ID: 6108981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic drug monitoring of clozapine and relapse--a retrospective study of routine clinical data.
    Ulrich S; Baumann B; Wolf R; Lehmann D; Peters B; Bogerts B; Meyer FP
    Int J Clin Pharmacol Ther; 2003 Jan; 41(1):3-13. PubMed ID: 12564740
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder.
    Chou JC; Douyon R; Czobor P; Volavka J; Cooper TB
    Psychiatry Res; 1998 Oct; 81(1):51-5. PubMed ID: 9829650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.
    Kelly MW; Perry PJ; Coryell WH; Miller DD; Arndt SV
    Psychopharmacology (Berl); 1990; 102(4):514-20. PubMed ID: 2096408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors affecting the clinical response to haloperidol therapy in schizophrenia.
    Bareggi SR; Mauri M; Cavallaro R; Regazzetti MG; Moro AR
    Clin Neuropharmacol; 1990; 13 Suppl 1():S29-34. PubMed ID: 2379182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.